Cambridge Discovery Chemistry, formerly Cambridge Combinatorial, a wholly owned subsidiary of Oxford Molecular Group, and Zeneca Agrochemicals, the crop protection and plant science business of AstraZeneca, announced a major chemistry research and development collaboration in mid-December.
Cambridge will take responsibility for Zeneca’s chemistry research facility within Zeneca’s R and D Center in Richmond, CA. The collaboration strengthens Cambridge’s business in North America and makes the company one of the first in its field to have research facilities in both the U.S. and Europe.
The merger agreement will continue despite the Dec. 2 announcement by the boards of AstraZeneca and Novartis AG that they would unite to create a new company called Snygenta AG. The merger is subject to conditions and approval but is expected to be completed in the second half of 2000.